JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.

Front Endocrinol (Lausanne) · 2022 · PMC9678079 · PMID 36419768

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In ER+ patient samples from TCGA breast cancer data, JMJD6 and ESR1 showed a trend towards negative correlation (Spearman, r 2 = -0.23) ( Figure 4A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.